Overview

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

Status:
Terminated
Trial end date:
2021-03-26
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in participants with manifest Huntington's disease (HD).
Phase:
Phase 3
Details
Lead Sponsor:
Hoffmann-La Roche